175 related articles for article (PubMed ID: 36892592)
1. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Chang J; Shen YJ; Shi T; Wang HF; Jin J; Zhu HH
Ann Hematol; 2023 May; 102(5):1275-1277. PubMed ID: 36892592
[No Abstract] [Full Text] [Related]
2. A balancing act: Blinatumomab use in a rare occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in an adolescent patient with Down syndrome.
Rav ES; Wahba A; Patnaik A; Toruner G; Hittle A; Toepfer L; Roth M; Cuglievan B; Nunez C; McCall D
Pediatr Blood Cancer; 2023 May; 70(5):e30191. PubMed ID: 36602024
[No Abstract] [Full Text] [Related]
3. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Whitlock JA; Peters C; Chen-Santel C; Chia V; Dennis RM; Heym KM; Katz AJ; Kelsh MA; Sposto R; Tu H; Tuglus CA; Verma A; Vinti L; Wilkes JJ; Zubarovskaja N; Zugmaier G; von Stackelberg A; Sun W
Leukemia; 2020 Sep; 34(9):2473-2478. PubMed ID: 32094465
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
5. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
Wolach O; Stone RM
Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
[TBL] [Abstract][Full Text] [Related]
6. Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.
Barlev A; Lin VW; Katz A; Hu K; Cong Z; Barber B
Adv Ther; 2017 Jan; 34(1):148-155. PubMed ID: 27873237
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Rambaldi A; Ritchie EK; Papayannidis C; Tuglus CA; Morris JD; Stein A
Eur J Cancer; 2021 Mar; 146():107-114. PubMed ID: 33588145
[TBL] [Abstract][Full Text] [Related]
8. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study.
Jabbour E; Patel K; Jain N; Duose D; Luthra R; Short NJ; Zugmaier G; San Lucas A; Velasco K; Tran Q; Zaman F; Konopleva M; Kantarjian H
Am J Hematol; 2021 Oct; 96(10):E379-E383. PubMed ID: 34161631
[No Abstract] [Full Text] [Related]
9. VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
Heraudet L; Galtier J; Favre S; Peyraud F; Cazaubiel T; Leroy H; Mottal N; Gros FX; Forcade E; Clément L; Dumas PY; Pigneux A; Leguay T
Br J Haematol; 2022 Aug; 198(3):523-527. PubMed ID: 35524489
[TBL] [Abstract][Full Text] [Related]
10. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
11. Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.
Kawakami Y; Imamura M; Imai C
Int J Hematol; 2024 May; 119(5):479-480. PubMed ID: 38492197
[No Abstract] [Full Text] [Related]
12. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
13. Approach to the Treatment of Philadelphia Chromosome-Negative B-cell ALL in Older Adults: Is Age Becoming just a Number?
Liu Y; Duong VH
Curr Hematol Malig Rep; 2023 Jun; 18(3):68-74. PubMed ID: 36877337
[TBL] [Abstract][Full Text] [Related]
14. Blinatumomab (Blincyto) for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 2015 May; 57(1468):e74-5. PubMed ID: 25941958
[TBL] [Abstract][Full Text] [Related]
15. Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Stein A; Franklin JL; Chia VM; Arrindell D; Kormany W; Wright J; Parson M; Amouzadeh HR; Choudhry J; Joseph G
Drug Saf; 2019 May; 42(5):587-601. PubMed ID: 30565020
[TBL] [Abstract][Full Text] [Related]
16. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
17. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab.
Mikhailova E; Gluhanyuk E; Illarionova O; Zerkalenkova E; Kashpor S; Miakova N; Diakonova Y; Olshanskaya Y; Shelikhova L; Novichkova G; Maschan M; Maschan A; Popov A
Haematologica; 2021 Jul; 106(7):2009-2012. PubMed ID: 33375769
[TBL] [Abstract][Full Text] [Related]
19. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
[TBL] [Abstract][Full Text] [Related]
20. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
Puzzolo MC; Radice G; Peragine N; de Propris MS; Mariglia P; Vignetti M; Vitale A; Bassan R; Annunziata M; Gaidano G; Rambaldi A; Chiaretti S; Guarini A; Foà R
Blood; 2021 Dec; 138(22):2290-2293. PubMed ID: 34297829
[No Abstract] [Full Text] [Related]
[Next] [New Search]
